Connect with us

Trends

India insulin pump market to reach USD 69.07 million

India’s insulin pump market is on track for steady growth, with projections indicating a rise from USD 34.66 million in 2024 to USD 69.07 million by 2032, reflecting a CAGR of 9.00%.

The Indian insulin pump market is experiencing growth driven by multiple factors. Firstly, the rising prevalence of diabetes, estimated at 77 million individuals, underscores the urgent need for effective management solutions like insulin pumps. As awareness about these advanced therapies increases and disposable incomes rise, more individuals are opting for insulin pumps over traditional injection methods. Supportive government policies and the potential expansion of insurance coverage further enhance affordability and accessibility, contributing to market expansion. Additionally, continuous technological advancements in insulin pump technology, including features like improved user interfaces and integration with continuous glucose monitoring systems, make these devices increasingly attractive to both patients and healthcare providers.

Furthermore, the market landscape is characterized by the participation of both established multinational corporations and a growing number of domestic players. Major global entities such as Medtronic, Abbott, and Insulet are prominent participants, leveraging their expertise and resources in the Indian market. Simultaneously, domestic companies like Biocon and Dr. Reddy’s Laboratories are entering the fray, indicating diversification of the market and potential for indigenous innovation. Geographically, the market spans across regions like North, South, East, West, and Central India, reflecting a widespread demand for insulin pump solutions nationwide.

Market drivers
Rising prevalence of diabetes in India:
India faces a significant challenge with diabetes, ranking second globally in the number of diabetic individuals. This growing population translates to a heightened need for effective diabetes management tools, including insulin pumps. As the prevalence of diabetes continues to rise, the demand for insulin pumps is expected to climb proportionally. For instance, with the increasing awareness of the benefits of insulin pump therapy among both patients and healthcare professionals, more patients are expected to adopt insulin pump therapy. This trend is likely to continue, given the serious health implications of unmanaged diabetes and the advantages of insulin pumps in maintaining optimal blood glucose levels.

Increasing disposable income and growing awareness:
India’s economic growth, which saw a GDP growth of 8.4% in the third quarter of FY24, has led to rising disposable incomes. For instance, in the city of Mumbai, the average monthly disposable salary after tax is around INR 76,906. This increase in disposable income is enabling a greater portion of the population to afford advanced diabetes management technologies like insulin pumps. For instance, the sales of insulin pumps have seen a increase year-on-year. Additionally, growing awareness about diabetes and its complications is prompting patients to explore treatment options beyond traditional injections. A survey conducted in 2023 revealed that about 60% of the urban population in India is aware of the complications associated with diabetes. This increased awareness fuels a willingness to invest in insulin pumps for improved blood sugar control. For instance, a study conducted in Delhi showed that 35% of the diabetic population is willing to switch from traditional injections to insulin pumps for better diabetes management. The prevalence of diabetes in India is over 8.8%, and more than 100 million people in India are estimated to be living with diabetes. This indicates a significant potential market for insulin pumps in the country. For instance, the city of Bangalore alone has a diabetic population of over 1.5 million, representing a substantial market for insulin pumps.

Technological advancements and user-friendly features:
The insulin pump market is witnessing continuous advancements in technology. For instance, newer pumps offer features like continuous glucose monitoring (CGM) integration, automated insulin delivery algorithms, and remote monitoring capabilities. These advancements provide more precise diabetes management and improve user experience, making insulin pumps a more attractive option for patients seeking greater control over their condition.

Government initiatives and insurance coverage:
The Indian government is increasingly recognizing the burden of diabetes on the healthcare system. As a result, initiatives are being taken to raise awareness, improve access to diabetes care, and potentially expand insurance coverage for insulin pumps. These efforts are expected to encourage wider adoption of insulin pumps by making them more affordable and accessible to patients who can benefit from them.

Market trends:
Technological advancements and expanding product portfolios:
In the realm of insulin pump therapy, manufacturers are spearheading a wave of technological advancements. For instance, Medtronic, a leading player in the market, launched the MiniMed 670G system, the world’s first hybrid closed-loop insulin pump. This new-generation pump is equipped with cutting-edge features such as seamless integration with continuous glucose monitoring (CGM) systems, providing real-time blood glucose data for more precise insulin delivery and enhanced glycemic control. Moreover, remote monitoring capabilities are being integrated into pumps, allowing healthcare providers and caregivers to remotely access patient data. This facilitates more effective treatment management and support. Another significant stride is the incorporation of artificial intelligence (AI) algorithms, empowering pumps with automated insulin delivery functions. This potentially simplifies therapy for patients, with an estimated 5% of Type 1 Diabetes Mellitus (T1DM) patients in India using insulin pumps. Concurrently, the market is witnessing an expansion in product offerings to cater to diverse patient needs. For instance, Insulet Corporation offers the Omnipod DASH system, a tubeless patch pump that provides an alternative to traditional insulin pumps.

Growing focus on affordability and accessibility:
In India, where insulin pump therapy has been historically perceived as a costly treatment option, there is a burgeoning emphasis on enhancing affordability and accessibility. This shift is fueled by various factors, including government initiatives aimed at policy changes and the expansion of insurance coverage. These initiatives can potentially make insulin pumps more accessible to a broader patient base. For instance, the National Health Mission in India has been instrumental in expanding access to healthcare services, including diabetes management. Additionally, manufacturers are proactively addressing affordability concerns by introducing lower-cost pump models and implementing flexible payment plans. This is democratizing access to this life-saving therapy. The concerted efforts toward increased affordability and accessibility are paramount for broadening the reach of insulin pump therapy in India, particularly among patients with limited financial resources. As a result, this is fostering better diabetes management and improving overall health outcomes.

Market concentration & characteristics:
The insulin pump market in India is currently characterized by limited penetration, primarily due to the dominance of traditional injectable therapies. However, as awareness and adoption of insulin pumps increase, the market is poised to attract new entrants, both domestic and international, leading to a more fragmented landscape. Government initiatives aimed at promoting insulin pump usage could further stimulate market growth and encourage local manufacturing. Nonetheless, there are indications of potential consolidation in the future, driven by technological advancements favoring players with strong R&D capabilities. Additionally, companies focusing on offering cost-effective solutions to address affordability concerns may gain a competitive advantage in this evolving market. Credence Research

Copyright © 2024 Medical Buyer

error: Content is protected !!